UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of July 2022

Commission File Number: 001-41421

Alvotech

(Translation of registrant’s name into English)

9, Rue de Bitbourg,

L-1273 Luxembourg,

Grand Duchy of Luxembourg

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

  ☒    Form 20-F  ☐    Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Press Release

On July 15, 2022, Alvotech (the “Company”) announced to the Nasdaq First North Growth Market that the Company filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission. The announcement is furnished as Exhibit 99.1 to this Report on Form 6-K.

EXHIBIT INDEX

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Exhibit 99.1

Published: 2022-07-15 10:00:00 CEST

Alvotech S.A.

Interim information

Filing of Preliminary Prospectus on Form F-1 with U.S. Securities and Exchange Commission

On 14 July 2022, Alvotech filed a Registration Statement on Form F-1 (the “Preliminary Prospectus”) with the U.S. Securities and Exchange Commission (the “SEC”). This registration statement is attached as a PDF.

Alvotech made this filing in connection with the registration rights of certain security holders under (i) various agreements Alvotech had entered into with security holders and investors related the business combination with Oaktree Acquisition Corp. II that closed on June 15, 2022, and (ii) the subscription agreements between Alvotech, Aztiq and Alvogen, respectively, pursuant to which Alvogen and Aztiq subscribed to 5,000,000 Shares for a subscription price of $10.00 per Share, the aggregate subscription price being set off against outstanding loan amounts payable by Alvotech. Alvotech also registered the issuance of Shares that may be issued upon the exercise of its outstanding warrants on this registration statement.

As stipulated in Alvotech’s Company Description, dated 21 June 2022, with a supplement, dated 22 June 2022 (the “Company Description”), Shares to be settled on the Nasdaq First North Growth Market (“Shares in Iceland”) have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”).

The filing is required pursuant to the Securities Act, and once Alvotech’s Preliminary Prospectus on Form F-1 has been declared effective by the SEC, Shares in Iceland, as well as other Shares and warrant referred to in the Preliminary Prospectus, will be considered registered under the Securities Act, as described in the Company Description.

Alvotech Investor Relations

Benedikt Stefansson

alvotech.ir[at]alvotech.com

Attachments:

F-1 as filed with SEC July 14 2022 364319ACL.pdf